Uracil misincorporation into
DNA is a consequence of
pemetrexed inhibition of
thymidylate synthase. The base excision repair (BER)
enzyme uracil-DNA glycosylase (UNG) is the major glycosylase responsible for removal of misincorporated
uracil. We previously illustrated
hypersensitivity to
pemetrexed in UNG(-/-) human
colon cancer cells. Here, we examined the relationship between UNG expression and
pemetrexed sensitivity in human
lung cancer. We observed a spectrum of UNG expression in human
lung cancer cells. Higher levels of UNG are associated with
pemetrexed resistance and are present in cell lines derived from
pemetrexed-resistant histologic subtypes (small cell and
squamous cell carcinoma). Acute
pemetrexed exposure induces UNG
protein and
mRNA, consistent with upregulation of
uracil-DNA repair machinery. Chronic exposure of H1299
adenocarcinoma cells to increasing
pemetrexed concentrations established
drug-resistant sublines. Significant induction of UNG
protein confirmed upregulation of BER as a feature of acquired
pemetrexed resistance. Cotreatment with the BER inhibitor
methoxyamine overrides
pemetrexed resistance in chronically exposed cells, underscoring the use of BER-directed
therapeutics to offset acquired drug resistance. Expression of UNG-directed
siRNA and
shRNA enhanced sensitivity in A549 and H1975 cells, and in
drug-resistant sublines, confirming that UNG upregulation is protective. In human
lung cancer, UNG deficiency is associated with
pemetrexed-induced retention of
uracil in
DNA that destabilizes DNA replication forks resulting in
DNA double-strand breaks and cell death. Thus, in experimental models, UNG is a critical mediator of
pemetrexed sensitivity that warrants evaluation to determine clinical value.